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Abstract: At present, only three risk factors for prostate cancer have been firmly established; 
these are all nonmodifiable: age, race, and a positive family history of prostate cancer. However, 
numerous modifiable factors have also been implicated in the development of prostate cancer. 
In the current review, we summarize the epidemiologic data for age, location, and selected 
behavioral factors in relation to the onset of prostate cancer. Although the available data are 
not entirely consistent, possible preventative behavioral factors include increased physical 
 activity, intakes of tomatoes, cruciferous vegetables, and soy. Factors that may enhance prostate 
 cancer risk include frequent consumption of dairy products and, possibly, meat. By comparison, 
alcohol probably exerts no important influence on prostate cancer development. Similarly, 
dietary supplements are unlikely to protect against the onset of prostate cancer in healthy men. 
Several factors, such as smoking and obesity, show a weak association with prostate cancer 
incidence but a positive relation with prostate cancer mortality. Other factors, such as fish 
intake, also appear to be unassociated with incident prostate cancer but show an inverse relation 
with fatal prostate cancer. Such heterogeneity in the relationship between behavioral factors 
and nonadvanced, advanced, or fatal prostate cancers helps shed light on the carcinogenetic 
process because it discerns the impact of exposure on early and late stages of prostate cancer 
development. Inconsistent associations between behavioral factors and prostate cancer risk 
seen in previous studies may in part be due to uncontrolled detection bias because of current 
widespread use of prostate-specific antigen testing for prostate cancer, and the possibility that 
certain behavioral factors are systematically related to the likelihood of undergoing screening 
examinations. In addition, several genes may modify the study results, but data concerning 
specific gene–environment interactions are currently sparse. Despite large improvements in our 
understanding of prostate cancer risk factors in the past two decades, present knowledge does 
not allow definitive recommendations for specific preventative behavioral interventions.
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Introduction
Prostate cancer is the most common cancer, excluding nonmelanoma skin cancer, 
among men in the USA and other industrialized societies. In 2010, it was estimated to 
account for nearly 220,000 new cancer diagnoses and over 30,000 deaths among US 
men.1 On a global scale, the incidence and mortality of prostate cancer varies widely.2 
While some of these differences can be attributed to variation in diagnostic intensity, 
the considerable heterogeneity in prostate cancer mortality across countries indicates 
that behavioral factors play an important role. The sizeable rise in the incidence and 
mortality of prostate cancer following migration from low-risk to high-risk countries 
further supports this hypothesis.3
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There are three nonmodifiable risk factors for  prostate 
 cancer: age, race, and a positive family history of prostate 
 cancer. In addition, a number of modifiable or behavioral 
factors have been found to be associated with prostate  cancer 
risk. While not firmly established, protective behavioral  factors 
may include physical activity and frequent consumption of 
tomatoes, cruciferous vegetables, and soy foods. In contrast, 
high dietary intakes of dairy products and meat may increase 
prostate cancer risk. Several factors, including smoking and 
obesity, are only weakly related to prostate cancer onset 
but are positively associated with prostate cancer mortality. 
By comparison, regular fish consumption shows little 
 association with prostate cancer incidence but may provide 
 protection against fatal prostate cancer. This article provides 
an overview of the epidemiologic literature regarding these 
behavioral factors, age, location, and their associations with 
prostate cancer risk.
Age
Prostate cancer incidence strongly increases with age. Based 
on US Surveillance, Epidemiology and End Results Program4 
statistics from 2000–2008, the incidence rate of prostate 
cancer is 9.2/100,000 for men aged 40–44 years. That rate 
increases sharply to 984.8/100,000 in men aged 70–74 years, 
after which it slightly decreases.4 Prostate cancer  typically 
develops slowly and the cancer may be  preceded by dysplastic 
lesions for many years, or even decades. Extrapolations from 
autopsy studies suggest that most men would have prostate 
cancer if they lived to be more than 100 years old.5 The 
number of prostate cancers found incidentally at autopsy, 
which had been asymptomatic and not a cause of death, 
suggests that small, localized prostate cancers can remain 
unrecognized for many years before progressing to clinically 
significant disease. Although the lifetime risk of developing 
microscopic prostate cancer for a man of 50 years is 42%, the 
risk of his dying of prostate cancer is only about 3%.6,7
Location
Incidence rates of prostate cancer tend to be higher in northern 
and central European countries than in southern and eastern 
European countries.8 In 2008, in Europe as a whole, the 
incidence rate of prostate cancer was 93.4/100,000, ranging 
from a low of 27.7 per 100,000 in the Ukraine to a high of 
183.1 per 100,000 in Ireland. In the USA, the incidence of 
prostate cancer is several times higher than in Japan. Also, US 
rates are 1.6 times higher among African–American men than 
among Caucasian men.9 Studies based on migration patterns 
show distinct changes in the incidence of prostate cancer. 
For example, rates of prostate cancer among Japanese 
migrants to Hawaii are intermediate between the rates in 
Japan and those for Caucasians in Hawaii.10
During the last two decades, changes have been observed 
in the incidence rates of prostate cancer in the USA and other 
industrialized countries,11 while prostate cancer mortality has 
remained relatively stable. In the USA, a strong increase in 
prostate cancer incidence occurred between 1985 and 1991, 
followed by a decrease in incidence until 1996. Beginning in 
1997, incidence rates have been leveling off.2 The rise in 
incidence rates in the mid-1980s is largely due to an increas-
ingly common use of prostate-specific antigen (PSA) as a 
method for early detection of prostate cancer. By 2001, 75% 
of American men aged 50 years old or older reported that they 
had undergone a PSA test at least once,12 while that statistic 
is lower in other countries, such as Germany.13 The use of 
PSA testing in the USA to detect prostate cancer in an early 
phase has shifted the spectrum of diagnosed cancers toward 
an increased diagnosis of moderately differentiated tumors 
(Gleason sum scores 5–7). PSA screening is less common 
in Germany than in the USA, but the procedure has altered 
the age distribution of prostate cancer cases in Germany as 
well; the mean age at diagnosis has declined from 73 years 
of age in 1980 to 69 years in 2006.14
Body size
Epidemiologic studies have generally shown weak positive 
associations between measures of obesity and total prostate 
cancer incidence. A meta-analysis of the relation of body 
mass index (BMI) to prostate cancer included 55,521 cases 
from 31 cohort studies and 13,232 cases from 25 case-control 
studies. It yielded a relative risk of total prostate cancer per 
5 kg/m2 increment of BMI of 1.05 (95% confidence interval 
[CI] = 1.01–1.08).15 Of note, the positive relation of BMI to 
prostate cancer was more pronounced for advanced disease 
(relative risk [RR] per 5 kg/m2 increment of BMI = 1.12; 
95% CI = 1.01–1.23), whereas the association was null for 
localized disease (RR per 5 kg/m2 increment of BMI = 0.96; 
95% CI = 0.89–1.03). In that meta-analysis, there was little 
evidence for a relation of central obesity to total prostate 
cancer, with weakly positive but statistically nonsignificant 
associations for waist circumference (RR per 10 cm incre-
ment = 1.03; 95% CI = 0.99–1.07) and waist to hip ratio (RR 
per 0.1 unit increment = 1.11; 95% CI = 0.95–1.30).
The greater risk seen for advanced prostate cancer and 
the lack of an association with obesity for nonadvanced 
prostate cancer indicates that the biological mechanisms 
underlying the association between adiposity and prostate 
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cancer are complex. The most salient hypotheses relate to the 
imbalance of various metabolic and hormonal  perturbations 
associated with adiposity. Certain metabolic alterations 
sustained in obese men, such as increased levels of insulin, 
insulin-like growth factor-1 (IGF-1), and leptin may increase 
prostate cancer risk.16,17 Other adiposity-related hormonal 
alterations, such as reduced concentrations of testosterone 
and higher levels of estrogen may decrease prostate cancer 
risk.18 Further complexity is added by the possibility that 
testosterone may differentially affect low-grade and high-
grade prostate cancers.19
Diabetes
Individuals with type 2 diabetes are characterized by hyper-
insulinemia, which may enhance the risk of prostate cancer 
through the promotion of tumor cell growth. However, 
numerous epidemiologic studies have shown a decreased 
risk of prostate cancer among men with diabetes. A recent 
meta-analysis of 19 studies (published up to 2005) found 
an inverse association between diabetes and prostate cancer 
(RR = 0.84; 95% CI = 0.76–0.93).20
The precise biological mechanisms underlying the 
relation of diabetes to prostate cancer remain speculative. 
Hyperinsulinemia is associated with reduced levels of 
insulin-like growth factor-binding protein (IGFBP) and sex 
hormone-binding globulin (SHBG) and enhanced levels of 
circulating IGF-1 and testosterone.21 IGF-1stimulates prostate 
tumor cell growth22 and is related to increased prostate 
cancer risk.23 As diabetes progresses to hypoinsulinemic 
stages, IGFBP and SHBG levels increase, presumably 
resulting in less bioavailable IGF-1 and testosterone 
levels. While available evidence does not indicate a strong 
association between testosterone levels and prostate cancer,24 
androgens have been found to induce prostate cancer cell 
proliferation in vitro,25 and low SHBG levels have been 
related to enhanced prostate cancer risk.18 Also, it remains 
possible that hyperglycemia has a direct adverse impact on 
the testosterone-synthesizing Leydig cells, adding a further 
explanation for a potential protective influence of diabetes 
on risk for prostate cancer.
Physical activity
Numerous epidemiologic studies have investigated the rela-
tionship between physical activity and prostate  cancer, and 
studies have provided both positive and negative associations. 
A recent meta-analysis of 19 cohort studies and 24 case-
control studies (published up to 2011) showed a small 
inverse association between physical activity and prostate 
cancer.26 The combined data from both types of studies 
yielded a RR of incident prostate cancer of 0.90 (95% 
CI = 0.84–0.95), when comparing the highest with the 
lowest levels of total physical activity. A slightly more pro-
nounced prostate  cancer risk reduction was observed with 
occupational  activity (RR = 0.81; 95% CI = 0.73–0.91), 
whereas the  relation with recreational activity was statistically 
nonsignificant (RR = 0.95; 95% CI = 0.89–1.00).  Studies that 
considered localized and advanced prostate cancer as distinct 
disease endpoints revealed no difference in risk estimates. 
The RR estimates that compared high versus low levels of 
total physical activity, for localized and advanced prostate 
cancer were 0.96 (95% CI = 0.87–1.05) and 0.94 (95% CI = 
0.80–1.10), respectively. Several studies27–29 examined physi-
cal  activity in relation to prostate cancer mortality and reported 
a decreased risk of fatal prostate cancer with higher levels of 
activity, with risk estimates ranging from 0.26 to 0.67. Thus, 
increased physical activity is associated with a small reduction 
in the risk of prostate cancer as a whole, and perhaps a modest 
to strong decrease in risk of fatal prostate cancer.
Biological pathways that affect whether physical activity 
potentially prevents prostate cancer include specific growth 
factors and hormones, such as insulin, IGF-1, and vitamin D. 
Physical activity boosts insulin sensitivity and reduces insulin 
levels,30 which enhances IGFBP-1 and decreases bioavailable 
IGF-1.21 Physical activity may also favorably affect prostate 
cancer through higher 25(OH) vitamin D levels associated 
with enhanced outdoor exposure to ultraviolet radiation.31 On 
the other hand, physical activity may decrease prostate cancer 
risk by augmenting antioxidant defense mechanisms and 
immune function,32 although direct evidence – linking exer-
cise-associated increases in oxidative defense and immunity 
to lower risk of prostate cancer – is currently unavailable. 
Physical activity may also decrease prostate cancer risk by 
preventing chronic low-grade inflammation, a condition that 
shows a positive association with prostate carcinogenesis.33 
Physical activity may indirectly influence prostate  cancer by 
preventing obesity, which has been positively related to prostate 
cancer mortality.34 Whether physical activity influences the 
risk of  prostate cancer through a pathway involving a reduction 
of testosterone concentrations remains speculative.35
Aspirin and nonsteroidal  
anti-inflammatory drugs
Chronic inflammation is involved in prostate cancer 
development, and aspirin and other nonsteroidal anti-
inflammatory drugs (NSAIDs) may play a role in the 
prevention of prostate cancer by inhibiting the activity of 
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cyclo-oxygenases – key enzymes involved in prostaglandin 
synthesis. A  meta-analysis of ten case-control and 14 cohort 
studies36 showed an inverse association between aspirin use 
and prostate cancer, with a pooled risk estimate comparing 
users with nonusers of 0.83 (95% CI = 0.77–0.89). By com-
parison, the relationship between nonaspirin NSAID use and 
prostate cancer was less pronounced and it did not reach for-
mal statistical significance (RR = 0.90; 95% CI = 0.80–1.01). 
A recent nested case-control study37 examined different 
classes of NSAIDs and found that use of propionates (eg, 
ibuprofen, naproxen) was related to a decreased risk of pros-
tate cancer (odds ratio [OR] = 0.89; 95% CI = 0.84–0.95), 
while use of other classes of NSAIDs was unrelated to risk. 
Taken together, these data suggest that aspirin and certain 
classes of nonaspirin NSAIDs may prevent the development 
of prostate cancer.
Sexual behavior and sexually 
transmitted diseases
Several case-control studies reported positive associations 
between a history of sexually transmitted diseases (STDs), 
in particular gonorrhea and syphilis, and the risk of prostate 
cancer.38 Most of these studies, however, were retrospective in 
design and are thus prone to bias. While most prospective 
studies have shown that a history of gonorrhea or syphilis 
is not associated with prostate cancer,39–41 one recent 
prospective study41 observed an increased risk of prostate 
cancer in Latino men living in the USA who had a history 
of gonorrhea (RR = 1.43; 95% CI = 1.07–1.91). There was 
a more pronounced risk among foreign-born US-based 
Latino men (RR = 1.87; 95% CI = 1.16–3.02) than US-born 
Latino men (RR = 1.15; 95% CI = 0.76–3.02). Apart from 
potential differences in prostate cancer detection rates, it 
remains possible that the latter group of men had not received 
timely STD treatment and may thus have experienced a more 
severe or a longer duration of the infection. Infections of the 
various types of herpes viruses (including human herpes virus 
type 8, herpes simplex viruses 1 and 2, cytomegaly virus, 
and Epstein–Barr virus) do not appear to increase the risk 
of prostate cancer.42 However, infection with Trichomonas 
vaginalis was associated with prostate cancer risk in two39,43 
of three available cohort studies,39,43,44 in particular with 
advanced and fatal prostate cancers.39,43 Infection with 
T. vaginalis is often asymptomatic in men and, if persistent, 
possibly cause chronic inflammation of the prostate.
Sexual behavior has been thought to be associated 
with prostate cancer for several reasons. Some factors 
that might produce this reasoning include an increased 
likelihood of acquiring an STD, having a high number of 
sexual partners, and having higher circulating testosterone 
levels. A meta-analysis (published in 2001) concluded 
from the data of 12 case-control studies that prostate 
cancer risk was increased with increasing sexual activity 
(OR = 1.2; 95% CI = 1.1–1.3, for an increase of three 
times per week).38 More recently, ejaculation frequency 
was found to be inversely related to prostate cancer risk 
in a prospective study (RR = 0.67; 95% CI = 0.51–0.89, 
for $21 vs 4–7 ejaculations per month), which was 
conf ined to nonadvanced prostate cancer, while no 
association was observed for advanced prostate cancer.45 
Although there is biological plausibility for an inverse 
association between ejaculation frequency and prostate 
cancer risk, ie, elimination of chemical carcinogens and 
toxins from the prostate or alteration of the composition 
of prostatic fluid through sexual activity,46 additional 
prospective information is required before firm conclu-
sions can be drawn.
Smoking
Smoking is estimated to cause about 30% of all cancers 
worldwide, but smoking has generally not been considered 
a risk factor for prostate cancer. However, a recent meta-
analysis of 24 cohort studies reported a statistically significant 
increase in prostate cancer risk amongst heavy smokers 
(RR = 1.22; 95% CI = 1.01–1.46, highest versus lowest 
cigarettes/day).47 In comparison, two studies showed that 
smoking afforded an apparent protective effect against 
developing nonadvanced48 or low-grade49 prostate cancer. 
Noncausal factors that may explain a potentially decreased 
risk of nonadvanced prostate cancer among smokers 
include lower PSA levels in smokers than nonsmokers,50 
and a lower likelihood that smokers will undergo regular 
prostate cancer screening examinations compared with 
nonsmokers.
In contrast to prostate cancer incidence, smoking is posi-
tively associated with prostate cancer mortality, with smokers 
having a 14% greater risk of dying from prostate cancer than 
nonsmokers (95% CI = 1.06–1.19).47 Smoking may promote 
the development of more aggressive, hormone-sensitive 
tumors through numerous mechanisms, including effects on 
sex steroid hormone levels, mutations in tumor suppressor 
genes such as p53, and continued exposure to carcinogens 
such as polycyclic aromatic hydrocarbons  contained in 
cigarette smoke.51
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Dietary factors
Fruits and vegetables
Because of their abundance of vitamins, minerals, and other 
secondary plant products, frequent consumption of fruits 
and vegetables has long been thought to decrease cancer 
incidence and mortality. However, most large cohort studies 
concluded that there is no strong protective effect of fruit 
and vegetable consumption on risk of prostate cancer.52–54 
Notwithstanding this, results from several studies indicate 
that specific components of fruits and vegetables, such as 
lycopene, or specific subgroups of fruits and vegetables, 
for instance, cruciferous vegetables, may be associated with 
decreased risk of prostate cancer.
Tomatoes and lycopene
Tomato products are the principal dietary source of 
bioavailable lycopene in the USA. Lycopene represents 
the most common carotenoid in human plasma and it is 
a potent singlet oxygen quencher.55 Frequent intake of 
lycopene or tomatoes has been associated with decreased 
risk of prostate cancer in numerous prospective and case-
control studies, and in several serum-based investigations.56 
However, a considerable number of studies have not been 
supportive. Thus, there has been intense debate regarding 
the true relation of lycopene to prostate cancer. Several 
factors may have contributed to the heterogeneity in 
results and their interpretations across available studies, 
including an insufficient contrast between high and low 
levels of lycopene in studies, lack of repeated measures of 
lycopene intake, inability of dietary questionnaires to assess 
key contributors of lycopene (such as tomato sauce), and 
unaccounted for variation in the bioavailability of lycopene 
across different food sources.57
The most recent available meta-analysis on tomato 
products and prostate cancer includes ten cohort studies 
and eleven case-control studies (published up to 2003).58 
Comparing extreme quintiles of intake, the RR of prostate 
cancer for intake of raw tomatoes was 0.89 (95% 
CI = 0.80–1.00) and for cooked tomatoes 0.81 (95% 
CI = 0.71–0.92). The major hypothesis concerning a 
potential benefit of tomato products on prostate cancer 
risk is that lycopene prevents oxidative DNA damage 
in prostate tissue by reducing exposure to cellular free 
radicals.59 However, there are other potential mechanisms 
and additional beneficial compounds in tomatoes, such 
as other carotenoids and phytochemicals and these may 
possibly afford protection also.
Cruciferous vegetables
Cruciferous vegetables represent a group of vegetables that 
are rich in glucosinolates, which are degraded to biologically 
active isothiocyanates and indoles. These compounds 
are thought to exert cancer protective effects by inducing 
detoxification enzymes such as glutathione-S-transferases 
(GSTs) and NADPH-quinone oxidoreductase, which are 
important in the metabolism of carcinogens.
In an analysis of the Health Professionals Follow-up 
Study, no association between cruciferous vegetables and 
prostate cancer was found among men who had undergone at 
least one PSA test in the previous six years,60 which indicates 
that detection bias due to screening is important to take into 
account. However, the Prostate, Lung, Colorectal and Ovarian 
Cancer Screening Trial,53 which was designed to control for 
prostate cancer screening, observed an inverse association 
between cruciferous vegetable intake and risk of extrapro-
static prostate cancer (RR = 0.60; 95% CI = 0.36–0.98, 
1.1 serving vs 0.1 serving/day). The only study thus far to 
estimate dietary intake of glucosinolates provided evidence 
for an inverse association with prostate cancer, in particular 
with low-grade disease.61
One possible explanation for the inconsistency concerning 
the relationship between cruciferous vegetable intake and 
prostate cancer is genetic heterogeneity in the enzymes that 
are induced by glucosinolates. Additionally, glucosinolates 
themselves are products of these enzymes. A nested case-
control study showed that polymorphisms in NQO1, GSTM1, 
and GSTT1 modified the association between glucosinolate 
intake and risk of prostate cancer.62 Another study also 
reported effect modification of the association between 
broccoli intake and risk of prostate cancer by GSTM1 allele 
status.63 However, the direction of the effect modification 
differed between those two studies, with an inverse relation 
among men with deletions of GSTM1 and GSTT1 in the 
former study, and an inverse relation among GSTM1 positive 
men in the latter study.
Soy products
Soy products contain a variety of compounds, in particular 
isoflavonoids that exert effects on estrogen and testosterone 
metabolism. There is growing evidence for a beneficial 
action of isoflavonoids on multiple cancer-related biological 
pathways, such as carcinogen bioactivation, cell-signaling, 
cell cycle regulation, angiogenesis, oxidative stress, and 
chronic inflammation.64 It has been speculated that the 
incidence of prostate cancer in Eastern Asia is lower than in 
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Western societies because of the high soy consumption in 
Asia. In a meta-analysis including five cohort and nine case-
control studies, total consumption of soy foods (OR = 0.74; 
95% CI 0.63–0.89, for high vs low consumption) and non-
fermented soy foods (OR = 0.70; 95% CI = 0.56–0.88) were 
inversely associated with prostate cancer risk.65 However, 
in that meta-analysis the inverse association between soy 
food consumption and prostate cancer risk was confined to 
Asian men, whereas no association was seen among stud-
ies on men from Western societies.65 Possible explanations 
for this observation include different types of soy foods 
consumed in Asian and Western countries, or that the low 
consumption of soy food in Western countries fails to reach 
the threshold needed to produce an inverse association with 
prostate cancer.
Fish
Fish is rich in polyunsaturated fatty acids such as eicosapen-
taenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3), 
which have anti-inflammatory properties and have been linked 
to decreased prostate cancer risk in laboratory  settings.66 Fatty 
acids are involved in the regulation of prostaglandin produc-
tion via the cyclo-oxygenase and lipoxygenase pathways, 
which play an important role in inflammation, proliferation, 
and angiogenesis. However, epidemiologic data in support 
of a protective relationship between fish intake and prostate 
cancer incidence has been limited. The most comprehen-
sive evidence to date comes from a recent meta-analysis of 
fish consumption and prostate cancer.67 That investigation 
encompassed data from 12 case-control studies including 
5777 prostate cancer cases and 12 cohort studies including 
13,924 prostate cancer cases. Comparing extreme quantiles 
of fish intake, analyses suggested a small decrease in risk of 
prostate cancer incidence from the case-control studies, with 
a pooled OR of 0.85 (95% CI = 0.72–1.00). Findings for the 
cohort studies were largely null, with a pooled RR for prostate 
cancer incidence of 1.01 (95% CI = 0.90–1.14). However, 
a strong risk reduction with frequent fish intake was noted for 
prostate cancer mortality, based on the results of four cohort 
studies. As compared to infrequent fish consumption (less 
than twice per month), eating fish more than three times per 
week was associated with a RR for prostate cancer mortality 
of 0.37 (95% CI = 0.18–0.74). The findings of a weak or null 
relationship between fish intake and overall prostate cancer 
incidence, and a strong inverse association between fish 
consumption and fatal prostate cancer suggest that the anti-
inflammatory properties of fish are specific to the prevention 
of aggressive, clinically relevant prostate cancers.
Meat
Meat is a rich source of several micronutrients such as 
B  vitamins and iron. However, meat is also rich in  saturated 
fats and cholesterol. In ecological studies, high meat con-
sumption has been found to be correlated with increased 
cancer incidence.68 A recent meta-analysis of 15 prospective 
studies did not observe an association between red meat con-
sumption and risk of total (RR = 1.00; 95% CI = 0.96–1.05 
per 100 g increment) or advanced prostate cancer (RR = 0.97; 
95% CI = 0.91–1.02). Similarly, there was no association 
between processed meat consumption and risk of total 
prostate cancer (RR = 1.02; 95% CI = 1.00–1.04 per 30 g 
increment).69
It has been speculated that it is not meat consumption per 
se but, in particular, meat prepared by grilling,  barbecuing, 
and frying that leads to the formation of polycyclic aromatic 
hydrocarbons and heterocyclic amines (HCA) that may 
increase the risk of prostate cancer. For example, a positive 
association between the intake of 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) and prostate cancer was 
seen in the Prostate, Lung, Colorectal and Ovarian Cancer 
Screening Trial, in particular, with advanced disease.70 HCAs 
are metabolized in the human body and may eventually form 
HCA-DNA adducts, which are thought to cause structural 
damage to DNA.71 In a group of 268 US men, grilled meat, 
in particular, red meat, was positively correlated with PhIP-
DNA adducts in prostate tumor cells, whereas the correlation 
with adducts in noncancerous cells was less pronounced.71
Dairy products
Dairy products are an abundant source of protein, calcium, 
and several B vitamins such as riboflavin. On the other hand, 
they are also rich in saturated fats, which have been shown 
to be positively associated with some cancers.68 A high 
consumption of dairy products has been associated with an 
increased prostate cancer risk in several, but not all, studies. 
A meta-analysis (including studies published up to 2006) 
revealed a positive association between dairy consumption 
and prostate cancer risk (RR = 1.13; 95% CI = 1.02–1.24, 
highest vs lowest quantile).72
The positive relationship between dairy consumption 
and prostate cancer seen in several studies led to the 
hypothesis that the causal factor may be calcium. Based on 
the observation that calcium intake is positively correlated 
with circulating levels of IGF-1,73 one potential biological 
mechanism linking calcium to prostate cancer risk is the IGF-1 
axis. A further possible mechanism involves the suppression 
of 1,25-dihydroxyvitamin D
3
 production by calcium.74 
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In a meta-analysis based on ten prospective studies, men with 
the highest intake of calcium (RR = 1.39; 95% CI = 1.09–1.77) 
were more likely to develop prostate cancer than men with 
the lowest intake.75 However, not all studies show a clear 
association between calcium intake and prostate cancer 
risk. One possible explanation for these varying results is an 
insufficient contrast between high and low calcium intakes 
in study populations. In addition, positive associations with 
prostate cancer, particularly with advanced disease, have 
been limited to studies that included assessments of very 
high calcium intakes of 2000 mg/day or more, an intake that 
is achievable only with supplemental calcium.76,77 However, 
the association between calcium supplement use and prostate 
cancer risk is not consistent in all studies.78 Thus, the relation 
of calcium supplement use to prostate cancer risk remains 
inconclusive.
Alcohol
The first metabolite of alcohol, acetaldehyde, is a potent 
carcinogen, and alcohol consumption is considered to 
be a risk factor for many cancers.68 In a meta-analysis of 
50 case-control and 22 cohort studies (published up to 
2010),79 the relative risk for any alcohol drinking com-
pared with non/occasional drinking was 1.06 (95% CI = 
1.01–1.10). In the European Prospective Investigation into 
Cancer and Nutrition cohort, alcohol consumption was 
not associated with prostate cancer risk, irrespective 
of beverage type and stage and grade of disease.80 By 
comparison, the National Institutes of Health-American 
Association of Retired Persons Diet and Health Study 
reported that consumption of 6+ alcoholic drinks/day was 
related to an increased risk of nonadvanced prostate cancer 
(RR = 1.25; 95% CI = 1.13–1.37), but there was no asso-
ciation with advanced disease and an inverse association 
with fatal prostate cancer.81 In the Health Professionals 
Follow-up Study, alcohol consumption was not associated 
with prostate cancer in the overall analysis but there was 
an increased risk of prostate cancer in men with binge-
drinking behavior.82 As prostate cancer possibly develops 
over many decades, it may be long-term drinking habits 
that are related to prostate cancer risk rather than drinking 
behavior close to diagnosis.
Tea and coffee
Several prospective studies found no statistically significant 
relations of coffee intake to prostate cancer.83–86 In contrast, 
a recent US cohort study87 reported an inverse association 
between high coffee consumption (6+ cups/day) and risk of 
prostate cancer (RR = 0.82; 95% CI = 0.68–0.98). When 
considering advanced and nonadvanced prostate cancers as 
separate endpoints, a strong inverse risk estimate emerged for 
advanced cancer (RR = 0.47; 95% CI = 0.28–0.77), whereas 
no relation remained for nonadvanced cancer (RR = 0.93; 
95% CI = 0.74–1.16). The authors of that study87 hypoth-
esized that the biological mechanisms through which frequent 
coffee consumption protects against advanced prostate cancer 
involve antioxidant, anti-inflammatory, or insulin-sensitizing 
activities of the numerous beneficial components contained 
in coffee, including lignans, phytoestrogens, and chlorogenic 
acids.
With respect to tea consumption, a recent meta-analysis88 
reported an inverse association between green tea con-
sumption and prostate cancer risk, which was confined to 
case-control studies. The authors did not find an association 
with black tea consumption. Intriguingly, results of a small, 
randomized, controlled trial suggest that green tea catechins 
inhibit the progression of high-grade prostate intraepithelial 
neoplasia to prostate cancer.89 Thus far, however, epidemio-
logic evidence regarding tea intake in relation to prostate 
cancer is largely confined to Asian men, who consume higher 
amounts of green tea than US or European men.
Dietary patterns
Dietary pattern analysis aims at integrating different aspects 
of the diet instead of analyzing the effects of single dietary 
components. Prospective studies have generally not identified 
specific dietary patterns associated with prostate cancer.90,91 
One exception is a cohort study that linked a Southern 
dietary pattern to decreased prostate cancer risk.92 The 
authors of that study, however, speculated that the observed 
inverse association was not explained by a Southern diet 
itself but rather, by a Southern lifestyle in general, which 
includes frequent sun exposure with enhanced vitamin D 
levels. Several case-control studies93–95 reported a positive 
association between a Western dietary pattern and prostate 
cancer, but the possibility of recall bias in those studies 
cannot be excluded as an explanation for the results. 
Thus, the relation of dietary patterns to prostate cancer 
remains unclear.
Dietary supplements
In a representative study in the USA, more than 50% of 
participants reported taking dietary supplements.96 Because 
of real or acclaimed beneficial effects of several dietary 
components present in dietary supplements, such as vita-
mins and minerals, dietary supplements are commonly used 
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to prevent chronic diseases, including cancer. The relation 
of dietary supplement use to prostate cancer risk has been 
examined in several studies, but the results from these inves-
tigations are heterogeneous, which is in part due to the wealth 
of dietary supplements used in the populations under study. 
Both the Cancer Prevention Study II and the National Insti-
tutes of  Health-American Association of  Retired Persons 
Diet and Health Study showed an increased risk of fatal 
prostate cancer among multivitamin users compared with 
nonusers.97,98 In the Carotene and Retinol Efficacy Trial study, 
there was no association between supplement use and risk of 
prostate cancer.99 However, men who were in the Carotene 
and Retinol Efficacy Trial intervention arm (beta-carotene 
plus retinyl palmitate) and additionally used other supple-
ments had an increased risk of aggressive prostate cancer. 
This association disappeared after discontinuation of the 
study supplements and the authors speculated that the effects 
of antioxidants on cellular processes may vary depending 
on the oxidative milieu of the tissue. In contrast, the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study, which 
focused on Finnish elderly male smokers, found that supple-
mentation of alpha-tocopherol (50 mg/d) was significantly 
associated with decreased prostate cancer risk.100 However, in 
the Selenium and Vitamin E Cancer Prevention Trial trial of 
over 35,000 men, which was designed to examine the effect 
of vitamin E and/or selenium supplementation on prostate 
cancer risk in healthy men, neither vitamin E nor selenium 
supplementation was significantly associated with prostate 
cancer risk.101
Challenges and future directions
The current review of the literature suggests that several 
behavioral factors are associated with the risk of prostate 
cancer. However, important questions remain to be addressed 
in future investigations. The spectrum of prostate cancer cases 
included in epidemiologic studies has changed consider-
ably over time. Studies conducted before the introduction 
of testing for elevated PSA contained a high proportion of 
prostate cancers that were diagnosed at later stages, whereas 
more recent studies comprise a large number of cases that 
are characterized by early lesions and lower tumor stages. 
As a consequence, exposures that play a prominent role 
in the early stages of prostate cancer development are still 
detectable as risk factors in current studies, while it has 
become increasingly challenging for current studies to detect 
risk factors for prostate cancer that play a role late in the 
carcinogenetic process. Larger studies may help solve the 
problem of low numbers of advanced and fatal prostate cancer 
cases in contemporary studies by creating cohort consortia. 
Furthermore, some men are more likely to undergo PSA 
screening examinations than others, and the likelihood of 
attending prostate cancer screening tests may systematically 
track with certain lifestyle and dietary factors. Thus, a care-
ful assessment of screening visits and their results is crucial 
to address potential detection bias in ongoing and future 
prostate cancer studies.
Men diagnosed with prostate cancer have a good survival 
rate if the cancer is detected early. With better treatment 
options, epidemiologic research should not only focus on 
risk factors for prostate cancer incidence, but also prostate 
cancer mortality. Smoking is a good example of a behav-
ioral factor that increases risk for prostate cancer mortal-
ity more strongly than prostate cancer incidence. Thus, 
further research that focuses on differences in associations 
with incident prostate cancer and fatal prostate cancer is 
warranted.
An additional reason for inconsistencies of results in 
prostate cancer studies is the likely differences that occur 
in the genes that regulate the metabolism of nutrients or 
carcinogens, as well as those that regulate the metabolism 
of sex steroid hormones and growth factors. So far, only 
a few studies have addressed whether genetic variants 
modify relations of dietary, behavioral, or hormonal factors 
to  prostate cancer risk. Data pooling will be necessary to 
examine these interactions as they usually require a very 
large number of study participants for adequate statistical 
power. Such collaborative work should help further clarify 
the etiology of this important disease.
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